The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study

• Published in: Pathology, research and practice research and practice, 2022-10, Vol.238, p.154128-154128
• Main Authors: Margiana, Ria, Sharma, Satish Kumar, Khan, Bilal Irshad, Alameri, Ameer A, Opulencia, Maria Jade Catalan, Hammid, Ali Thaeer, Hamza, Thulfeqar Ahmed, Babakulov, Sharaf Khamrakulovich, Abdelbasset, Walid Kamal, Jawhar, Zanko Hassan
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2022.154128

In recent years, the COVID-19 pandemic has become one of the most crucial scientific issues in the world, and efforts to eradicate the disease are still ongoing. The acute inflammatory reaction associated with this disease is associated with several complications such as cytokine storm, multiple organ damage, lung fibrosis, and blood clots. PTX3, as part of the humoral innate immune systems, is one of the acute-phase proteins that perform various functions, such as modulating inflammation, repairing tissue, and recruiting immune cells. PTX3 is increased in people with SARS-CoV-2, and its level decreases with proper treatment. Therefore, it can be regarded as a suitable marker for the prognosis of the COVID-19 and evaluating the effectiveness of the treatment method applied. However, some studies have shown that PTX3 can be a double-edged sword and develop tumors by providing an immunosuppressive environment.